• Featured publications

    Here you can see some of the recent peer-reviewed publications in which the Cell Regulation panel has been used to identify novel protein signatures.


    Enroth S, Berggrund M, Lycke M, Broberg J, Lundberg M, Assarsson E, Olovsson M, Stålberg K, Sundfeldt K and Gyllensten U. High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. (2019) Communications Biology, doi: 10.1038/s42003-019-0464-9
    Article link>

    The signature described in the above publication included two proteins identified from assays in the Cell Regulation panel:

    • PROK1 (Prokineticin-1)
    • TACSTD2 (Tumor-associated calcium signal transducer 2)

    Shen Q, Polomb K, Williams C, Souza de Oliveira FM, Guergova-Kuras M, Lisacek F, Karlsson N, Roviello F and Kamali-Moghaddama M. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. (2019) EBioMedicine, 10.1016/j.ebiom.2019.05.044
    Article link>

    The 19-protein signature described in the above publication included five proteins identified from assays in the Cell Regulation panel:

    • DDAH1 (N(G),N(G)-dimethylarginine dimethylaminohydrolase 1)
    • FLI1 (Friend leukemia integration 1 transcription factor)
    • ZBTB17 (Zinc finger and BTB domain-containing protein 17)
    • APBB1IP (Amyloid beta A4 precursor protein-binding family B member 1-interacting protein)
    • KAZALD-1 (Kazal-type serine protease inhibitor domain-containing protein 1)

    Other associations presented for proteins from the Cell Regulation panel were:

    1. Six proteins significantly differently expressed in tumor tissue compared to corresponding normal tissues (see Fig 2D)
    2. Nine proteins expressed in tumor tissues that were associated with clinical variables (see Table 2)
    3. GCNT1 (Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase) identified as the most significantly differentially expressed protein in serum comparing early stage GC-patients and controls (see Fig 4A).

    Go back to the Cell Regulation panel page →